Andrea Sartore-Bianchi Selected Research

regorafenib

1/2019	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
1/2019	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
12/2016	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.
1/2016	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).
3/2014	Regorafenib in metastatic colorectal cancer.
5/2013	Regorafenib for metastatic colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea Sartore-Bianchi Research Topics

Disease

89	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 05/2005
67	Neoplasms (Cancer) 10/2022 - 04/2005
11	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2012
11	Disease Progression 01/2022 - 06/2012
5	Circulating Neoplastic Cells 05/2021 - 02/2014
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2017
4	Microsatellite Instability 01/2021 - 01/2019
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 05/2004
3	Carcinoma (Carcinomatosis) 11/2021 - 04/2005
3	Malignant Mesothelioma 10/2007 - 11/2002
2	Exanthema (Rash) 11/2022 - 06/2016
2	Anemia 11/2022 - 04/2005
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 11/2019
2	Fatigue 01/2020 - 06/2016
2	Rectal Neoplasms (Rectal Cancer) 01/2020 - 09/2019
2	Colonic Neoplasms (Colon Cancer) 01/2019 - 10/2013
1	Turcot syndrome 01/2022
1	Bites and Stings (Sting) 05/2021
1	Respiratory Insufficiency (Respiratory Failure) 02/2021
1	Thymoma (Thymic Carcinoma) 02/2021
1	Myasthenia Gravis 02/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	Adenocarcinoma 01/2021
1	Breast Neoplasms (Breast Cancer) 09/2020
1	Inflammation (Inflammations) 01/2020

Drug/Important Bio-Agent (IBA)

24	ErbB Receptors (EGF Receptor)IBA 01/2022 - 05/2005
24	Cetuximab (Erbitux)FDA Link 11/2021 - 05/2005
23	Panitumumab (Vectibix)FDA Link 11/2022 - 05/2005
17	Monoclonal AntibodiesIBA 11/2019 - 05/2005
15	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2009
11	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2022 - 05/2004
8	Circulating Tumor DNAIBA 05/2021 - 02/2014
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2014
7	AntibodiesIBA 01/2022 - 08/2010
6	Trastuzumab (Herceptin)FDA Link 01/2021 - 11/2015
6	Pharmaceutical PreparationsIBA 01/2021 - 01/2017
6	Lapatinib (GW572016)FDA Link 01/2021 - 11/2015
6	regorafenibIBA 01/2019 - 05/2013
5	entrectinibIBA 10/2022 - 12/2015
5	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
5	DNA (Deoxyribonucleic Acid)IBA 05/2021 - 01/2018
5	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 12/2016
5	Phosphotransferases (Kinase)IBA 01/2017 - 06/2013
5	Calcibiotic Root Canal SealerIBA 12/2016 - 02/2014
4	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2017
3	Cell-Free Nucleic AcidsIBA 01/2021 - 07/2017
3	pertuzumabIBA 01/2021 - 01/2020
3	Leucovorin (Folinic Acid)FDA Link 01/2020 - 09/2019
2	pembrolizumabIBA 10/2022 - 01/2022
2	VaccinesIBA 01/2022 - 01/2022
2	Anaplastic Lymphoma KinaseIBA 01/2022 - 12/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 04/2005
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2020
2	trastuzumab deruxtecanIBA 01/2021 - 01/2020
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2020
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 12/2016
2	Capecitabine (Xeloda)FDA Link 01/2020 - 10/2013
2	Biological ProductsIBA 07/2017 - 05/2014
2	Dacarbazine (DIC)FDA LinkGeneric 01/2017 - 04/2013
2	Codon (Codons)IBA 06/2016 - 10/2010
2	Growth Factor ReceptorsIBA 03/2014 - 05/2005
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2014 - 06/2012
2	MMEIBA 10/2007 - 11/2002
2	Interleukin-2 (IL2)IBA 10/2004 - 11/2002
1	larotrectinibIBA 10/2022
1	dostarlimabIBA 10/2022
1	disitamab vedotinIBA 03/2022
1	trastuzumab duocarmazineIBA 03/2022
1	mRNA VaccinesIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	avelumabIBA 11/2021
1	InterferonsIBA 05/2021
1	Cisplatin (Platino)FDA LinkGeneric 02/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2021
1	SteroidsIBA 02/2021
1	Pyridostigmine Bromide (Pyridostigmine)FDA LinkGeneric 02/2021
1	Intravenous Immunoglobulins (IVIG)FDA Link 02/2021
1	encorafenibIBA 01/2021
1	Granzymes (Granzyme)IBA 01/2021
1	Everolimus FDA Link 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021
1	ChromatinIBA 01/2021
1	Apoptosis Regulatory ProteinsIBA 01/2021
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2021
1	abemaciclibIBA 09/2020
1	palbociclibIBA 09/2020
1	ribociclibIBA 09/2020
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2020

Therapy/Procedure

58	Therapeutics 10/2022 - 06/2005
14	Drug Therapy (Chemotherapy) 11/2022 - 05/2005
5	Immunotherapy 01/2022 - 05/2004
4	Retreatment 02/2022 - 02/2019
4	Precision Medicine 01/2021 - 11/2011
1	Contraindications 02/2021
1	Critical Care (Surgical Intensive Care) 02/2021
1	Plasma Exchange 02/2021
1	Artificial Respiration (Mechanical Ventilation) 02/2021
1	Radiotherapy 02/2021